At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
sildenafil +1 moredrug
Likely dose
sildenafil 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
In Brief
A Phase 2 clinical trial evaluating sildenafil and placebo for Sickle Cell Disease and Priapism. Completed, enrolled 13 participants across 1 site.
Detailed Summary
This research is being done to evaluate if the phosphodiesterase type 5 (PDE5) inhibitor sildenafil has an effect on the frequency of recurrent priapism and the quality of life of males with sickle cell disease (SCD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease, Priapism
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJul 2009
Primary CompletionNov 2012
Study CompletionDec 2013
TodayJul 2026
First PostedJul 17, 2009
Enrollment StartJun 1, 2008
Primary CompletionNov 1, 2012
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 17.0 years ago
Interventions
sildenafildrug
sildenafil 50 mg tablet daily for first 8 weeks (phase 1), and then sildenafil 50 mg tablet daily for final 8 weeks (phase 2)
placeboother
placebo 50 mg tablets daily for first 8 weeks (phase 1), and then sildenafil 50mg tablet daily for final 8 weeks (phase 2)